Get Instant Loan up to ₹10 Lakh!
Pfizer Inc. has offered to supply its vaccine to the Indian government at a “not-for-profit” price as part of its strategy to provide distinct prices for the vaccine based on the economic profile of the country.
“For India, Pfizer has offered a not-for-profit price for its vaccine for the government immunization programme. We continue to be in discussions with the government and remain committed to making our vaccine available for deployment in India’s immunization programme,” a Pfizer spokesperson said in a statement on Thursday.
The statement followed certain media reports speculating about the price of the vaccine in India.
The US firm said it has adopted variable pricing as part of its strategy to provide vaccines exclusively to the government for its covid-19 immunization programme.
“This would be our approach in India as well. Further, in all our agreements, Pfizer has adopted a distinct pricing structure for high, middle, and low/lower-middle-income countries, consistent with our commitment to work towards equitable and affordable access for our covid vaccine for people around the world,” the company said.
The company spokesperson was not immediately available to give details on what price it has offered the government.
In the US, it is charging $19.5 per dose from the government to supply the vaccine, through which it expects to make some profit despite chief executive officer Albert Bourla calling it “pandemic pricing”. In the European Union, Pfizer has significantly raised prices over the past few months from €12 to €15.5 and then €19.5 ($23) per dose for orders in 2022-23.
Pfizer has forecast $15 billion in additional sales from the vaccine alone in 2021, with its overall profit estimated at $4 billion, according to various reports.
Catch all the Business News , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.